Trovagene Inc (TROV) Stock Price & Overview
NASDAQ:TROV
Current stock price
The current stock price of TROV is 1.19 null. Today TROV is down by -0.83%. In the past month the price increased by 47.08%. In the past year, price decreased by -62.34%.
TROV Key Statistics
- Market Cap
- 13.103M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.80
- Dividend Yield
- N/A
TROV Stock Performance
TROV Stock Chart
TROV Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to TROV. When comparing the yearly performance of all stocks, TROV is a bad performer in the overall market: 85.67% of all stocks are doing better.
TROV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TROV. Both the profitability and financial health of TROV have multiple concerns.
TROV Earnings
TROV Forecast & Estimates
TROV Financial Highlights
Over the last trailing twelve months TROV reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS increased by 66.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -4732.65% | ||
| ROA | -140.47% | ||
| ROE | N/A | ||
| Debt/Equity | 0.11 |
TROV Ownership
About TROV
Company Profile
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics.
Company Info
Trovagene Inc
11055 FLINTKOTE AVENUE
SAN DIEGO CA 92121
CEO: Thomas H. Adams
Phone: 858-952-7570
Trovagene Inc / TROV FAQ
Can you describe the business of Trovagene Inc?
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics.
What is the stock price of Trovagene Inc today?
The current stock price of TROV is 1.19 null. The price decreased by -0.83% in the last trading session.
Does Trovagene Inc pay dividends?
TROV does not pay a dividend.
What is the ChartMill technical and fundamental rating of TROV stock?
TROV has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of Trovagene Inc (TROV)?
Trovagene Inc (TROV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.8).